Join a panel of BKD Trusted Advisors™ and HFMA for a discussion on the reimbursement implications of the IPPS and OPPS final rule for federal fiscal year 2021, changes to the 340B drug program, recent actions by participating drug manufacturers, and more regulatory updates as looming requirements come to fruition in the coming weeks.
Upon completion of this program, participants will be able to:
- Discuss the highlights and reimbursement implications of the Medicare Final Rule for the FYE 9/30/21
- Describe changes to 340B drug payments and trends in this program
- Identify updates to other looming and impending regulatory issues